DURECT. has filed a patent for a method to treat various inflammatory conditions, including Alzheimer’s disease, asthma, and fibromyalgia, by administering specific compounds. The method aims to address a wide range of health issues associated with inflammation, potentially offering new treatment options. GlobalData’s report on DURECT gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on DURECT, Nanoparticle drug conjugates was a key innovation area identified from patents. DURECT's grant share as of January 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of inflammatory conditions using specific compounds
A patent application (Publication Number: US20230372361A1) discloses a method for treating inflammatory conditions associated with Epstein-Barr virus infection in a subject. The method involves administering compounds such as 25-hydroxycholesterol-3-sulfate (25HC3S) or its salts to the subject. The inflammatory conditions targeted by this method include a wide range of ailments such as dental pulp inflammation, psoriasis, ulcerative colitis, Alzheimer's disease, asthma, and fibromyalgia, among others. The compounds can be administered in various forms and dosages, ranging from oral administration to injection, with the pharmaceutical composition formulated in unit dosage form for ease of use.
Furthermore, the method allows for flexibility in dosing, with the compounds administered once to three times per day in amounts ranging from 0.001 mg/kg/day to 100 mg/kg/day based on the subject's body mass. The pharmaceutical composition can be in solid form, such as a powder, tablet, or capsule, or in liquid form, with the compound solubilized or dispersed in the liquid carrier. The composition can be stored in sealed vials, ampoules, syringes, or bags to ensure stability and sterility. Overall, this method presents a novel approach to treating inflammatory conditions associated with Epstein-Barr virus infection, offering a wide range of potential applications and dosing options for effective treatment.
To know more about GlobalData’s detailed insights on DURECT, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
